PR84590

GARDANNE, France, June 30, 2020 /PRNewswire=KYODO JBN/ --

- French/American Contract Services Organisation boosts its offer to CNS/PNS

drug development companies

Today Neuro-Sys, pharmacological Contract Research Services company

specialising in the R&D and in vitro testing of molecules used to treat

neurogenerative diseases in the Central Nervous System and Peripheral Nervous

System, announces the launch of in vivo services.

This latest investment in state-of-the-art facilities allows Neuro-Sys to offer

animal models and behavioural testing that uses digital tracking systems for

the testing of candidate molecules, to its existing in vitro, and to new

customers.

Of this latest development Chief Scientific Officer Noelle Callizot said: "We

continue to conduct research to refine our knowledge of the pathological

pathways and to develop our innovative in vitro models.  At the same time, it's

important that our in vivo activity validates and enhances our in vitro work,

allowing our customers a seamless process in their drug development programmes."

A record year

The significant investment completes a record year for Neuro-Sys' in vivo

business, with turnover increasing by 60% over the previous year.  The company

was also voted a "Top 10 Bioanalytical services company" by Pharma Tech

Outlook, "Best International drug development and discovery company for 2019"

by Global Health & Pharma, UK, "Drug Development Company of the year" for 2020

by Corporate Live Wire, UK and recently one of the "50 Leading Companies of the

year" by US magazine The Silicon Review and "Research & Development reference

for neurodegenerative diseases' by Biotech Finances, confirming its global

standing.

About Neuro-Sys

Neuro-Sys is a French Contract Research Organization founded in 2013.  Its team

of expert pharmacists and neuropharmacologists specialises in developing the

understanding of neurodegenerative diseases of the central nervous system (CNS)

and peripheral nervous systems (PNS) and the R&D of molecules used to treat

them. It offers the screening of neuro active molecules using leading models

that mimic their action in neurodegenerative diseases, and mode of action

research.  

Neuro-Sys develops specific preclinical in vitro and in vivo models of CNS and

PNS diseases. These models allow the understanding of the mode of action of

molecules used in the treatment of diseases such as Alzheimer's, Parkinson's,

Amyotrophic lateral sclerosis, Multiple sclerosis, Huntington's,

Adrenoleukodystrophy, Multiple System Atrophy, Charcot-Marie Tooth.

Logo - https://mma.prnewswire.com/media/1196886/Neuro_Sys_Logo.jpg

Press contact: Cindy Sangnier

Email: cindy.sangnier@neuro-sys.com

Source:  Neuro-Sys